Lauren Stevens

Dr. Stevens has more than 25 years’ experience, including extensive corporate experience as a senior executive and general counsel. The primary focus of Dr. Stevens’s legal practice is to develop and implement global IP strategies with an emphasis on obtaining strong patent protection, assessing third party patent estates, and resolving potential issues related to enforceability, patentability, and validity.   Dr. Stevens has procured U.S. and foreign patents with an emphasis on small molecule pharmaceutical chemistry, prepared Orange Book listability, patentability, validity, and infringement analyses and FDA patent listing forms. Dr. Stevens has extensive experience with approved drug products, including AGAMREE®, COBENFYTM, KEVEYIS®, CAMBIA®,  ROLVEDON®, INGREZZA®, CRENESSITY®, ONGENTYS®, ORLISSA®, DUEXIS®, RAYOS®, VIMOVO®, PENNSAID® 2%, RAVICTI®, KRYSTEXXA®, ACTIMMUNE®, PROCYSBI®, and BELVIQ®, and many drugs prior to FDA approval, including bexicaserin, emcitate, clofutriben, bempikibart, etrasimod, ralinepag, and temanogrel.

Dr. Stevens earned her J.D. degree from Stanford Law School and her Ph.D. in organic chemistry from Yale University.

Dr. Stevens is a member of the California State Bar and is registered to practice before the U.S. Patent and Trademark Office.